

## **Cynata Receives Notice of Allowance from US Patent Office for Unique Cymerus™ Technology**

**Melbourne, Australia; 26 August 2021:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The Notice of Allowance is sent to the applicant when the USPTO intends to issue a patent. Cynata anticipates that the patent will be granted around early November 2021, with an expiration date of 14 March 2037.

The patent application, entitled “Colony Forming Medium and Use Thereof”, is wholly owned by Cynata.

The patent will extend the already strong IP protection of the Cymerus manufacturing platform and its unique ability to yield highly consistent mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products. Cynata’s extensive IP portfolio already includes issued patents in a wide range of commercially important markets, including Japan, Europe and the USA.

**Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:**

*“The award of a US patent is a one of the most important achievements for innovative companies such as Cynata. The US is the largest market for regenerative medicine and to have patent protection to 2037 and beyond is paramount to our growth and long-term value. This milestone patent is one of a number of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology and de-risking its commercialisation potential. The ability of the Cymerus platform to enable the production of consistent, high-quality mesenchymal stem cells at scale is a major competitive and manufacturing advantage and key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide.”*

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)

Lauren Nowak, Media Contact, +61 (0)400 434 299, [laurenmaree@live.com.au](mailto:laurenmaree@live.com.au)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus



MSC products in osteoarthritis (Phase 3) and in patients with respiratory failure are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), diabetic foot ulcers, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**